Late last month, Teva kicked off a roadshow to meet shareholders of its buyout target, Mylan, and find out what price it'll need to put forth to convince them to support a deal. As Mylan starts up its own roadshow, its message is clear: It's categorically opposed to a tie-up with the Israeli drugmaker, and investors can't force one, either.
MorphoSys pulled the trigger on a deal for partner Lanthio Pharma, paying €20 million ($22 million) for the shares it didn't already own and picking up a handful of peptide candidates.
No surprise that the health industry is setting records, M&A-wise. According to PricewaterhouseCoopers, life sciences companies inked 35 deals worth $166.3 billion--more than all of 2014's transactions combined--in Q1.
Montreal-headquartered CRO JSS Medical Research is reaching into India, buying out Max Neeman International as it expands around the globe.
As market watchers wonder whether Gilead Sciences is on the verge of a blockbuster buyout, the Big Biotech inked a small deal that will beef up its efforts in the growing field of epigenetics.
Alexion jumped into the M&A game today, striking a deal to acquire the rare-disease biotech Synageva for $8.4 billion in cash and stock in a deal that gives shareholders a big premium and the industry another example of the fast-rising valuations in the biotech world.
Mylan may be demanding more than $100 per share from suitor Teva if it wants to talk takeover. But for itself--and its executives--its expectations aren't nearly that high.
Since before Teva even made its now-rejected $40 billion offer to buy Mylan, its target's exec chairman, Robert Coury, has been pretty down on the idea, citing a potential culture clash between the two companies. While Teva CEO Erez Vigodman has said he thinks they'd get along just fine, the rival drugmakers do have a few big differences between them--including their approach to executive compensation.
On pace to reap $29 billion in revenue this year thanks to its surging hepatitis C franchise, Gilead Sciences has the cash to pull off a big deal or two, and management is eyeing a slew of late-stage opportunities.
Hold it right there, Mylan, Teva said in a Wednesday letter to that company's executive chairman. A couple days after receiving a scathing rejection to its $40 billion buyout bid, the Israeli drugmaker has a few things it wants to set straight.